Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 18/20 | 0.62 |
| ▸ | CYP11B1 | P15538 | 16/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10176226 | 0.87 | CYP11B2 (0.58) | CYP11B2CYP11B1CYP3A4HTR2BHTR6 | |
| SCHEMBL168295 | 0.85 | HTR2B (0.67) | CYP11B2CYP11B1CYP3A4HTR2BHTR6 | |
| SCHEMBL10248895 | 0.83 | CYP11B2 (0.51) | CYP11B2CYP11B1CYP3A4HTR2BHTR6 | |
| SCHEMBL10176217 | 0.83 | CYP11B2 (0.62) | CYP11B2CYP11B1CYP3A4 | |
| SCHEMBL10249002 | 0.81 | CYP11B2 (0.49) | CYP11B2CYP11B1CYP3A4HTR2BHTR6 | |
| SCHEMBL10252540 | 0.81 | CYP11B2 (0.49) | CYP11B2CYP11B1CYP3A4HTR2BHTR6 | |
| SCHEMBL10249024 | 0.81 | SMN1; SMN2 (0.47) | CYP11B2CYP11B1 | |
| SCHEMBL10248916 | 0.81 | CYP11B2 (0.48) | CYP11B2CYP11B1CYP3A4HTR2BHTR6 | |
| SCHEMBL10248982 | 0.80 | CYP11B2 (0.47) | CYP11B2CYP11B1CYP3A4HTR2BHTR6 | |
| SCHEMBL17896608 | 0.79 | CYP11B2 (0.66) | CYP11B2CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461181-B2 | Fused heterocyclic compound and use thereof | SUMITOMO CHEMICAL COMPANY, LTD. (JP) | 2013-06-11 | — | — | US | disclosed |
| US-8273764-B2 | Fused heterocyclic compounds and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-09-25 | — | — | US | disclosed |
| US-20120178779-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED | 2012-07-12 | — | — | US | disclosed |
| US-20120015975-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178779-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | C3AR1, C9, C5 | CYP11B2 611/4885CYP11B1 491/4885CYP3A4 285/4885 |
| US-20120015975-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | C3AR1, C9, C5 | CYP11B2 611/4885CYP11B1 491/4885CYP3A4 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.